Interferon β-la treatment of multiple sclerosis

Interferon Therapy of Multiple Sclerosis

Volumn , Issue , 1997, Pages 343-352

  Herndon, Robert M ^a  

^a G V SONNY MONTGOMERY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0344867991     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (19)

1. Jacobs L, O’Malley J, Freeman A, Ekes R. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 1981; 214:1026-1028.
2. Jacobs L, O’Malley J, Freeman A, Ekes R. Intrathecal interferon in multiple sclerosis. Arch Neurol 1982; 39:609-615.
3. Emodi G, Just M, Hernandez R, et al. Circulating interferon in man after administration of exogenous human leukocyte interferon. J Natl Cancer Inst 1975; 54:1045-1049.
4. Smith RA, Norris F, Palmer D, et al. Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration. Clin Pharmacol Ther 1985; 37:85-88.
5. Jacobs L, Herndon R, Freeman, A, et al. Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbation of multiple sclerosis. Lancet 1986; 2:1411-1413.
6. Jacobs L, Salazar A, Herndon R, et al. Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis: results of a multicenter double-blind study. Arch Neurol 1987; 44:589-595.
7. Flenniken A, Galabru J, Rutherford M, et al. Expression of interferon-induced genes in different tissues of mice. J Virol 1988; 62:3077-3083.
8. Wong GH, Bartlett PH, Clark LI, et al. Inducible expression of H-2 and la antigens on brain cells, Nature 1984; 310:688-691.
9. Jacobs L, Munschauer FE. Treatment of multiple sclerosis with interferons. In: Rudick RA, Goodkin DE, eds. Treatment of Multiple sclerosis: Trial Design, Results and Future Perspectives. London: Springer-Verlag 1992: 223-250.
10. The IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind placebo-controlled trial. Neurology 1993; 43: 655-661.
11. Bornstein M, Miller A, Slagle S, et al. A pilot trial of COP-1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987; 317:408-414.
12. Goodkin DE, Cookfair D, Wende K, et al. Inter- and intrarater scoring agreement using grade 1.0 to 3.5 on the Kurtzke expanded disability status scale. Neurology 1992; 42:859-863.
13. Jacobs L, Cookfair D, Rudick R, et al. A Phase III Trial of Intramuscular Recombinant interferon Beta for Exacerbating-Remitting Multiple Sclerosis: Design and Conduct of Study; Baseline Characteristics of Patients. Multiple Sclerosis 1995; 1:118-135.
14. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39:285-294.
15. Gomi K, Morimoto M, Inoue A, et al. Pharmacokinetics of human recombinant interferon-β in monkeys and rabbits. Gann 1984; 75:292-300.
16. Alam J, Biogen Corp. Personal communication.
17. Challoner PB, Smith KT, Parker JD et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci 1995; 92: 7440-7444.
18. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta lb in the Treatment of Multiple Sclerosis. Final Outcome of the Randomized Trial. Neurology 1995; 45:1277-1285.
19. Sediq SA, Revesz KJ, Lassman AB, Miller JR. Antibodies to interferon β in patients with multiple sclerosis: detection and clinical effects. Neurology 1996; 42:A136.